The APTIMA HPV 16 18/45 Genotype Assay is intended to test specimens from women with APTIMA HPV Assay positive results and is approved for two uses:
• Adjunctively with the APTIMA HPV Assay in women 30 years and older in combination with cervical cytology to assess the presence or absence of specific high-risk genotypes 16, 18 and/or 45.
• Adjunctively with the APTIMA HPV Assay in women 21 years or older with atypical squamous cells of undetermined significance (ASC-US) cervical cytology results to assess the presence or absence of specific high-risk HPV genotypes 16, 18 and/or 45. The results of this test are not intended to prevent women from proceeding to colposcopy.
"The introduction of the APTIMA HPV 16 18/45 Genotype Assay enhances our HPV product offering on the TIGRIS platform," said Rob Cascella, President and Chief Executive Officer of Hologic. "We are pleased to now offer the most comprehensive portfolio of products that address the cervical cancer screening market and we look forward to maintaining our leadership in this important field."